Created in 2006, UNITAID is largely financed by a small tax on airline tickets and last year invested $30 million to roll out a new rapid test for tuberculosis, known as GeneXpert.
Last year, UNITAID released a study that demonstrates exactly what a country would need to do to implement an FTT. The study found that the introduction of such a tax on a national basis should have no significant negative impact on national financial markets.
We need to diversify how we fund the global fight against diseases like malaria. The term for this is "innovative financing for development." The world's laboratory for innovative financing is located in Geneva, in a small outpost of the UN family called UNITAID.
Drug companies who participate in the patent pool hand over their patents to UNITAID, which makes those patents available to generic drug manufacturers. Part of the deal is that the generic drugs can only be sold in lower-income countries.
It's quite ironic that on one hand there has never been such strong mobilization and acknowledgement of global health needs, and still, the funding and policies do not proportionately match the momentum or awareness.